Indian J Pharm Close
 

Figure 2: (a) Effect of bromocriptine on vascular reactivity to adrenaline (1 μg/kg), (b) noradrenaline (1 μg/kg), and (c) phenylephrine (1 μg/kg) in fructose-induced metabolic syndrome. Group I: vehicle; Group II: bromocriptine (10 mg/kg i.p); Group III: fructose (66% p.o.); Group IV: fructose + bromocriptine; Group V: fructose + bromocriptine + metformin (350 mg/kg); Group VI: fructose + bromocriptine + pioglitazone (10 mg/kg); Group VII: fructose + bromocriptine + insulin (2IU, s.c). Each value represents mean ± S.E.M. (n = 5). #Group II, III compared to Group I. *Groups IV, V, VI, and VII compared to Group III. ###,***P<0.001. (Oneway ANOVA followed by Dunnett's test)

Figure 2: (a) Effect of bromocriptine on vascular reactivity to adrenaline (1 μg/kg), (b) noradrenaline (1 μg/kg), and (c) phenylephrine (1 μg/kg) in fructose-induced metabolic syndrome. Group I: vehicle; Group II: bromocriptine (10 mg/kg i.p); Group III: fructose (66% p.o.); Group IV: fructose + bromocriptine; Group V: fructose + bromocriptine + metformin (350 mg/kg); Group VI: fructose + bromocriptine + pioglitazone (10 mg/kg); Group VII: fructose + bromocriptine + insulin (2IU, s.c). Each value represents mean ± S.E.M. (<i>n</i> = 5). #Group II, III compared to Group I. *Groups IV, V, VI, and VII compared to Group III. ###,***<i>P</i><0.001. (Oneway ANOVA followed by Dunnett's test)